Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Seeking Alpha / 16 hours ago 1 Views
Comments